---
title: "Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings"
id: "plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0361953"
published_at: "2026-11-03T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Sex Differences in ICI Survival for Advanced NSCLC: Meta-analysis Findings
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-15-sex-difference-in-survival-benefits-of-immune-checkpoint-inhibitors-in-advanced
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0361953)
- **Published At:** 2026-11-03T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The authors pooled 42 phase 3 randomized controlled trials, drawing on 25,827 patients (18,772 male; 7,055 female) to compare **immune checkpoint inhibitors** (ICIs) versus chemotherapy for advanced **non-small cell lung cancer** (NSCLC). - Investigators reported that ICIs improved both overall survival (OS) and progression-free survival (PFS) in males (OS HR 0.74; PFS HR 0.59) and females (OS HR 0.83; PFS HR 0.76). The source supplied these pooled hazard ratios and corresponding heterogeneity statistics. - The study team calculated pooled treatment-by-sex interaction hazard ratios and found a statistically greater benefit for males than females for OS (interaction HR 0.90; P = 0.01) and PFS (interaction HR 0.82; P = 0.0006). - Subgroup analyses showed sex differences concentrated in ICI monotherapy settings, including anti‑PD‑1 monotherapy and patients with **PD-L1** ≥50%; however, OS subgroup signals lost significance after False Discovery Rate correction while several PFS subgroup signals remained significant after correction. - The authors noted no significant sex-based differences when ICIs were combined with chemotherapy. - Meta-regression identified ICI type and race as sources of heterogeneity for males and females in various outcomes; PD‑L1 expression associated with PFS heterogeneity in females. - The GRADE assessment rated OS evidence as moderate and PFS evidence as low quality for both sexes; risk of bias was often high due to open-label designs. - Sensitivity analyses (leave-one-out and exclusion of trials with ≤30 female patients) produced robust pooled estimates according to the authors’ report. - The investigators cautioned that baseline imbalances, underrepresentation of females in trials, and potential confounding (for example, smoking prevalence and differential chemotherapy sensitivity) limit causal interpretation and require purpose-built RCTs to confirm sex-specific effects. - The study team deposited the trial-level extraction matrix in an open repository; full trial-level methodological details, dosing, and individual patient covariate distributions were not exhaustively reported in the source article.
## Clinical Analysis & Structured Key Points
Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Background Whether sex influences the survival benefit of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) remains uncertain. Methods We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus up to April 1, 2026, for randomized controlled trials (RCTs) comparing ICIs with chemotherapy and reporting overall survival (OS) or progression-free survival (PFS) stratified by sex. A random-effects model was used for meta-analysis. Results Sixty-three publications (reporting 42 phase 3 RCTs) involving 25,827 patients (18,772 male; 7,055 female) were included. Compared with chemotherapy, ICIs significantly improved both OS and PFS in males (OS: HR 0.74 [95% CI 0.71–0.78]; PFS: HR 0.59 [95% CI 0.54–0.64]) and females (OS: HR 0.83 [95% CI 0.77–0.90]; PFS: HR 0.76 [95% CI 0.66–0.86]). Pooled treatment-by-sex interaction analyses demonstrated significantly greater OS (interaction HR = 0.90 [95% CI 0.84–0.97]; P = 0.01) and PFS (interaction HR = 0.82 [95% CI 0.73–0.92]; P = 0.0006) benefits in males than in females. In subgroup analyses, sex‑based differences in OS reached statistical significance in patients receiving ICI monotherapy (P = 0.02), including those treated with anti‑PD‑1 monotherapy (P = 0.04) and those with PD‑L1 expression ≥50% (P = 0.02). However, these differences did not persist after the False Discovery Rate (FDR) correction (adjusted P = 0.07, 0.10, and 0.07, respectively). In contrast, sex‑based differences in PFS remained statistically significant after FDR correction in the ICI monotherapy (adjusted P = 0.001), anti‑PD‑1 monotherapy (adjusted P = 0.001), and PD‑L1 ≥ 50% (adjusted P = 0.004) subgroups. No significant sex‑based differences in either OS or PFS were observed among patients treated with ICI plus chemotherapy. Conclusions Although ICIs are superior to chemotherapy in both sexes, the PFS benefit of ICI monotherapy appears to be attenuated in females relative to males. Given the imbalances in baseline confounders coupled with the underrepresentation of females in the included trials, these findings should be interpreted with caution and warrant confirmation in future RCTs designed specifically to investigate sex‑based differences. Citation: Liu T, Song D, Chen J, Yao J, Liao J, Dang J (2026) Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis. PLoS One 21(11): e0361953. https://doi.org/10.1371/journal.pone.0361953 Editor: Jincheng Wang, Hokkaido University: Hokkaido Daigaku, JAPAN Received: May 11, 2026; Accepted: October 19, 2026; Published: November 3, 2026 Copyright: © 2026 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: All relevant data are within the paper and its Supporting Information files. Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Introduction Currently, immune checkpoint inhibitors (ICIs) represent the preferred treatment for advanced non-small cell lung cancer (NSCLC) lacking targetable oncogenic driver mutations. Among potential biomarkers for ICI response, programmed cell death ligand-1 (PD-L1) expression on tumor cells has been clinically validated as a predictor of treatment efficacy. Additionally, patient characteristics such as age [ 1 ] and smoking status [ 2 ] have also been associated with ICI efficacy. Sex represents another biological factor potentially influencing ICI outcomes. Preclinical studies indicate that sex hormones can regulate the PD-1/PD-L1 axis and modulate PD-L1 expression [ 3 ]. Furthermore, comprehensive analyses of genome-wide transcriptome data and tumor samples in NSCLC have revealed sex-specific differences in antitumor immunity and immune evasion mechanisms [ 4 ]. Nevertheless, the clinical relevance of sex difference in ICI efficacy remains controversial. Although multiple meta-analyses [ 5 – 19 ] have investigated this association across various malignancies, their findings have been inconsistent. These discrepancies may arise from methodological limitations, including restricted sample sizes, inadequate follow-up durations, and the inclusion of heterogeneous cancer types, all of which could compromise the reliability of pooled estimates. Given the recent publication of numerous randomized controlled trials (RCTs) and updated long-term survival data, a contemporary synthesis of the evidence is warranted. Therefore, we conducted an updated systematic review and meta-analysis to clarify the impact of sex on ICI treatment outcomes in advanced NSCLC. Methods Literature search and inclusion criteria We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [ 20 ]. Two authors (TL and DS) independently searched PubMed, Embase, the Cochrane Library, Web of Science, and Scopus for eligible studies published up to April 1, 2026. The search strategy and specific terms are detailed in S1 Table ( S3 File ). Studies were included based on the following criteria: (1) phase 2 or 3 RCTs comparing ICIs (administered as monotherapy or in combination) with chemotherapy in patients with advanced NSCLC; and (2) availability of overall survival (OS) or progression-free survival (PFS) data stratified by sex. When multiple publications originated from the same RCT, the publication reporting the most recent or comprehensive data was selected. Data extraction and risk of bias assessment Two authors (TL and DS) independently extracted the following data: (1) trial characteristics: trial name, first author, publication year, study design, geographical region, number of patients by sex, median follow-up duration, ICI agent, CT regimen, treatment modality (monotherapy/combination), and treatment line; (2) patient characteristics: age, Eastern Cooperative Oncology Group (ECOG) performance status, histological subtype, and PD-L1 expression level; (3) outcomes: hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for OS and PFS, stratified by sex. The risk of bias of the included trials was assessed using the Cochrane Risk of Bias Tool [ 21 ], which consists of the following domains: sequence generation, allocation concealment, blinding, incomplete data, selective reporting, and other bias. The trials were finally classified as low (all domains indicated as low risk), high (one or more domains indicated as high risk), and unclear risk of bias (more than three domains indicated as unclear risk). Statistical analysis The primary outcome was OS. Statistical analyses were performed using R software (version 4.5.3) with the meta package. Given the anticipated clinical and methodological heterogeneity across the included studies, pooled HRs were calculated using a random-effects model with inverse-variance weighting. The between-study variance (τ 2 ) was estimated using the restricted maximum likelihood (REML) estimator in the primary meta-analyses. For meta-analyses involving a limited number of studies (n ≤ 5), we applied the Hartung-Knapp-Sidik-Jonkman (HKSJ) method [ 22 , 23 ] to adjust the confidence intervals. This method employs a variance correction and a t-distribution with k − 1 degrees of freedom, yielding more conservative interval estimates when between-study heterogeneity is imprecisely estimated. For trials with two intervention arms sharing a common control group (IMpower-150, POSEIDON, and RATIONALE-307), a multivariate meta-analysis approach [ 24 , 25 ] was used to pool the two HRs; this approach accounts for the correlation between comparisons and avoids treating the shared control arm as independent information. Heterogeneity was assessed using Cochran’s Q test and quantified by the I 2 statistic, with values of 25%, 50%, and 75% considered to indicate low, moderate, and high heterogeneity, respectively. Meta-regression analysis was conducted to explore potential sources of heterogeneity. Pre-specified subgroup analyses were performed when at least three trials were available, stratified by race, histology, PD-L1 expression level, treatment modality (ICI monotherapy vs. combination therapy), and treatment line (first-line vs. subsequent lines). To quantify the differential efficacy of ICIs between sexes, we first calculated the treatment-by-sex interaction HR for each trial as the ratio of the male-specific HR (ICI vs. chemotherapy) to the female-specific HR; these trial-specific ratios were then pooled using a random-effects model, with a two-sided P < 0.05 considered statistically significant. To account for multiple testing in subgroup interaction analyses, we applied the False Discovery Rate (FDR) correction [ 26 , 27 ] to adjust P-values. Sensitivity analyses were performed to evaluate the robustness of the primary findings, including leave-one-out analyses (sequentially omitting one trial at a time) and analyses excluding trials with a critically low number of female patients (n ≤ 30). Publication bias was assessed using funnel plots and Egger’s regression test [ 28 ]. Results Study selection and characteristics The initial literature search yielded 6582 records. After screening titles and abstracts, 6483 articles were excluded. The remaining 99 full-text articles were assessed for eligibility. Ultimately, 63 publications [ 29 – 91 ], reporting data from 42 phase 3 RCTs involving a total of 25,827 patients (18,772 male; 7,055 female), were included in the meta-analysis. The study selection process is summarized in Fig 1 . Among the 42 phase 3 RCTs included, 15 were conducted in Asian countries, 6 in non-Asian countries, and 21 involved multi-regional populations. Twenty RCTs evaluated ICI monotherapy and twenty-two evaluated ICI combination therapy. ICIs were administered as first-line (1L) therapy in 32 RCTs and as second- or later line (≥2L) therapy in 10 RCTs. Common chemotherapy regimens were cisplatin or carboplatin combined with pemetrexed or paclitaxel in the 1L setting, and docetaxel in the ≥ 2L setting. Most patients had an ECOG score of 0–1. The proportion of never smokers was 17% (n = 4343). The median sample size per trial was 380 (interquartile range [IQR], 318–532) for males and 116 (IQR, 88–217) for females. The median follow-up duration across trials was 26.0 months (IQR, 16.3–34.4). Key trial characteristics and survival outcomes are summarized in Table 1 . We have deposited the raw data extraction matrix (an Excel file containing individual trial‑level hazard ratios, standard errors, and sample sizes) in the Zenodo open repository ( https://doi.org/10.5281/zenodo.21437774 ). Download: PNG larger image TIFF original image Table 1. Characteristics and outcomes of included trials. https://doi.org/10.1371/journal.pone.0361953.t001 Download: PNG larger image TIFF original image Fig 1. Literature search and selection. ICIs, immune checkpoint inhibitors. https://doi.org/10.1371/journal.pone.0361953.g001 Effect of ICIs on OS and PFS by sex Compared with chemotherapy, ICIs significantly improved both OS and PFS in both males (OS: HR = 0.74, 95% CI: 0.71–0.78, I 2 = 40%; PFS: HR = 0.59, 95% CI: 0.54–0.64, I 2 = 70%) and females (OS: HR = 0.83, 95% CI: 0.77–0.90, I 2 = 35%; PFS: HR = 0.76, 95% CI: 0.66–0.86, I 2 = 63%) ( Figs 2 and 3 ). However, the pooled treatment-by-sex interaction HRs favored males significantly more than females for both OS (0.90, 95% CI: 0.84–0.97; P = 0.01) and PFS (0.82, 95% CI: 0.73–0.92; P = 0.0006), indicating a significantly greater treatment benefit from ICIs in males ( Figs 2 and 3 ). Download: PNG larger image TIFF original image Fig 2. Forest plots of hazard ratios comparing overall survival between ICIs and CT and the interaction between treatment efficacy and sex. ICI, immune checkpoint inhibitor; CT, chemotherapy; HR, hazard ratio; CI, confidence interval. https://doi.org/10.1371/journal.pone.0361953.g002 Download: PNG larger image TIFF original image Fig 3. Forest plots of hazard ratios comparing progression-free survival between ICIs and CT and the interaction between treatment efficacy and sex. ICI, immune checkpoint inhibitor; CT, chemotherapy; HR, hazard ratio; CI, confidence interval. https://doi.org/10.1371/journal.pone.0361953.g003 Subgroup analysis In subgroup analyses for OS ( Fig 4 ), ICIs significantly prolonged OS compared with chemotherapy across most subgroups for both sexes, including Asian and non‑Asian populations, non‑squamous cell carcinoma (non‑SCC), PD‑L1 expression ≥1%, 1L and ≥2L settings, and both ICI monotherapy (anti‑PD‑1 or anti‑PD‑L1) and ICI plus chemotherapy. Notably, significant OS improvements were observed among males but not among females in the squamous cell carcinoma (SCC), dual ICI therapy, and PD‑L1 expression ≥50% subgroups (all patients in the PD‑L1 ≥ 50% subgroup received ICI monotherapy). The pooled treatment-by-sex interaction HR was 0.73 (95% CI: 0.57–0.95; P = 0.02) for the PD-L1 ≥ 50%, 0.89 (95% CI: 0.80–0.98; P = 0.02) for the ICI monotherapy, 0.87 (95% CI: 0.76–0.99; P = 0.04) for anti-PD-1 monotherapy, and 0.82 (95% CI: 0.69–0.96; P = 0.03) for dual ICI therapy subgroups, indicating a significantly greater OS benefit for males in these subgroups. However, after the FDR correction, these sex differences did not retain statistical significance (P = 0.07, 0.07, 0.10, and 0.09, respectively). Download: PNG larger image TIFF original image Fig 4. Subgroup analyses of overall survival according to sex and the interaction between treatment efficacy and sex. ICI, immune checkpoint inhibitor; CT, chemotherapy; SCC, squamous cell carcinoma; L, line; HR, hazard ratio; CI, confidence interval. * P-values after the False Discovery Rate correction. https://doi.org/10.1371/journal.pone.0361953.g004 In PFS subgroup analyses ( Fig 5 ), ICIs significantly improved PFS in males across all subgroups; for females, significant PFS benefit was observed only in subgroups of Asian, SCC, non-SCC, 1L setting, and ICI plus chemotherapy. Significant sex-based difference in PFS benefit favoring males was observed in subgroups of Asian (P = 0.0007), PD-L1 expression ≥1% (P < 0.0001), PD-L1 expression ≥50% (P = 0.0008), 1L setting (P = 0.02), ≥ 2L setting (P = 0.04), ICI monotherapy (P < 0.0001), and anti-PD-1 monotherapy (P = 0.0001). After FDR correction, the sex differences remained significant in the Asian (P = 0.004), PD‑L1 ≥ 1% (P = 0.001), PD‑L1 ≥ 50% (P = 0.004), ICI monotherapy (P = 0.001), and anti‑PD‑1 monotherapy (P = 0.001) subgroups. Download: PNG larger image TIFF original image Fig 5. Subgroup analyses of progression-free survival according to sex and the interaction between treatment efficacy and sex. ICI, immune checkpoint inhibitor; CT, chemotherapy; SCC, squamous cell carcinoma; L, line; HR, hazard ratio; CI, confidence interval. * P-values after the False Discovery Rate correction. https://doi.org/10.1371/journal.pone.0361953.g005 Forest plots detailing the subgroup analysis results are shown in S1–S27 Figs ( S3 File ). The GRADE assessment The overall quality of evidence (GRADE rating) for OS was moderate for both males and females. For PFS, the evidence quality was low for both sexes. In OS subgroup analyses, most evidence was rated as moderate quality. Exceptions with low-quality evidence were: SCC, and dual ICI subgroups for males; and non-Asian, non-SCC, and ICI plus chemotherapy combination subgroups for females. Detailed GRADE assessments are presented in S2 Table ( S3 File ). Meta-regression analysis Multivariable meta‑regression analyses revealed that ICI type (P = 0.03) and race (P = 0.03) were significant sources of heterogeneity for OS and PFS, respectively, in males ( S3 Table , S3 File ). In females, ICI type (P = 0.04) and race (P = 0.04) were significantly associated with heterogeneity for OS, whereas PD‑L1 expression (P = 0.03) was significantly associated with heterogeneity for PFS ( S3 Table , S3 File ). Sensitivity analysis The pooled HRs for males and females and the interaction HRs were robust, with no substantial changes in leave‑one‑out analyses ( S28–S31 Figs , S3 File ) or after excluding trials with ≤30 female patients in the intervention arms (CheckMate-017, IMpower-110, RATIONALE-307, CameL-sq, ORIENT-12, and ORIENT-3; S32 and S33 Figs , S3 File ). Assessment of included trials and publication bias Twelve trials [ 38 , 40 , 45 , 46 , 61 , 78 , 80 , 83 , 86 , 88 ] were assessed as having a low risk of bias. The remaining 30 trials were classified as having a high risk of bias, primarily due to their open-label design leading to lack of blinding of participants and personnel ( S34 Fig , S3 File ). Egger’s test results indicated no significant publication bias for either OS (males: P = 0.19; females: P = 0.65) or PFS (males: P = 0.13; females: P = 0.96). Corresponding funnel plots are shown in S35 Fig ( S3 File ). Discussion This meta-analysis demonstrated that ICIs significantly prolonged both OS and PFS compared with chemotherapy in male and female patients with advanced NSCLC. Notably, male patients derived significantly greater survival benefits from ICIs than female patients. Subgroup analyses revealed that significant sex-based differences in OS and PFS benefits were observed among patients receiving ICI monotherapy (including anti-PD-1 monotherapy and those with PD-L1 expression ≥50%), but not among those treated with ICI plus chemotherapy. The observed sex difference in treatment efficacy may be attributed to underlying biological mechanisms. Genomic and tumor microenvironment analyses reveal that female NSCLC patients exhibit greater T-cell dysfunction, elevated expression of inhibitory immune checkpoints, and a higher abundance of immunosuppressive cells compared to males [ 4 ]. Furthermore, clinical studies consistently report a lower prevalence of high PD-L1-expressing tumors in females compared to males [ 92 – 96 ]. Collectively, these factors suggest a reduced efficacy of ICI monotherapy in females. In addition, evidence indicates that females may have a higher response to chemotherapy than males [ 97 , 98 ], which could further diminish the relative benefit of ICI monotherapy when compared with a chemotherapy control arm. However, the sex-based OS difference for ICI monotherapy (including anti‑PD‑1 monotherapy) lost statistical significance after FDR correction, despite the PFS difference remaining significant. It is therefore highly probable that the observed differences are at least partly driven by unbalanced baseline confounders For example, women generally have a lower smoking prevalence than men, and ICIs are less effective in smokers than in never‑smokers [ 2 ]. In addition, females were generally underrepresented in trials, particularly in major Asian trials utilizing anti‑PD‑1 agents, which may confound sex‑specific effect estimates. Therefore, this finding should be interpreted with caution and warrants validation in future RCTs specifically designed to investigate sex‑based differences. The comparable efficacy of ICI plus chemotherapy between sexes may be explained by the ability of chemotherapy to enhance tumor antigenicity. Although female tumors may inherently possess weaker antigenicity, the addition of chemotherapy can increase tumor mutational burden [ 99 ], thereby promoting im
## Related Clinical Research

- [Chromeno[8,7-d]oxazole Lead AT-11: A CDK16 Inhibitor with Improved Solubility and Antitumor Activi](https://medichelpline.com/clinical-feed/pubmed-42822357.md) (DOI: 10.1016/j.bioorg.2026.110559)
- [Perioperative ivonescimab ± chemotherapy Yields High MPR in Resectable NSCLC (Phase 2)](https://medichelpline.com/clinical-feed/nature-1-perioperative-ivonescimab-with-or-without-chemotherapy-in-resectable-non-small.md)
- [XDH and ITPA linked to prognosis and cisplatin response in NSCLC: integrated bioinformatics and la](https://medichelpline.com/clinical-feed/pubmed-42972208.md) (DOI: 10.1007/s10142-026-02100-x)
- [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md)
- [SLFN11 as a biomarker of cisplatin sensitivity in pediatric solid tumors](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-slfn11-enhances-cisplatin-sensitivity-in-pediatric-cancer-via-activation-of.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.